MDT
Medtronic plc
MDT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MDT overall, supported by stronger fundamentals and stronger modeled upside.
MDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
MDT's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $101 | — |
| Cheap | 24x | $98.52 | -2.4% |
| Current | 25x | $101 | — |
| Fair | 27x | $111 | +9.9% |
| Expensive | 33x | $135 | +34% |
Historical ranges are pointers, not guarantees.
MDT's PE is in its cheap range at 25x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MDT in the historical PE scenario, which offers more potential upside but is not a forecast.
MDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for MDT, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.16 | +52% |
| Q3 2026 | $4.06 | +12% |
| Q2 2026 | $3.73 | +3.3% |
| Q1 2026 | $3.58 | +8.5% |
| Q4 2025 | $3.70 | +13% |
| Q3 2025 | $3.62 | +22% |
| Q2 2025 | $3.61 | +31% |
| Q1 2025 | $3.30 | +5.1% |
| Q4 2024 | $3.28 | +6.8% |
MDT has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.8B | +14% |
| Q2 2026 | $9.8B | +9.9% |
| Q1 2026 | $9B | +8.7% |
| Q4 2025 | $9B | +6.6% |
| Q3 2025 | $8.6B | +8.4% |
| Q2 2025 | $8.9B | +3.9% |
| Q1 2025 | $8.3B | +2.5% |
| Q4 2024 | $8.4B | +5.2% |
MDT's revenue has grown year over year for 14 quarters in a row: $9.8B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +1.2 points |
| Q2 2026 | 19% | +3 points |
| Q1 2026 | 16% | -3.6 points |
| Q4 2025 | 19% | -0.2 points |
| Q3 2025 | 17% | +0.7 points |
| Q2 2025 | 16% | +3.8 points |
| Q1 2025 | 20% | +1.5 points |
| Q4 2024 | 19% | +2.2 points |
MDT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MDT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +121% |
| Q2 2026 | $2.1B | +0.8% |
| Q1 2026 | $2.3B | +9.7% |
| Q4 2025 | $457M | -18% |
| Q3 2025 | $584M | +25% |
| Q2 2025 | $2.1B | -12% |
| Q1 2025 | $2.1B | -1.5% |
| Q4 2024 | $554M | +177% |
MDT generated $6.1B in free cash flow over the past year, up 16% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MDT on cash flow, with more consistent year-over-year improvement.
MDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -0.2% | -2M shares |
| 3 years | -3.7% | -48.7M shares |
| 5 years | -5.3% | -71.3M shares |
| Available history | -4.9% | -66.3M shares |
MDT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $267M |
| Q2 2026 | $435M |
| Q1 2026 | $105M |
| Q4 2025 | $372M |
| Q3 2025 | $123M |
| Q2 2025 | $274M |
| Q1 2025 | $181M |
| Q4 2024 | $288M |
MDT spent $1.2B buying back its own shares over the past year, up 36% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.0x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.4x | Elevated |
MDT's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.0 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MDT on leverage, with a lower net debt burden relative to earnings.
MDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.9 | Neutral |
| Stochastic | 81.3 | Overbought |
MDT's weekly RSI is 66 (neutral) and its Stochastic is 81 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MDT PE vs Healthcare Sector
| Metric | MDT | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 3.8% below |
| PE % | 22 | 29 | 7 pts below |
MDT is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MDT on valuation relative to its sector.
MDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $94.1 | 7.3% above |
| 20 week MA | $90.6 | 11% above |
| 50 week MA | $90.0 | 12% above |
| 100 week MA | $89.9 | 12% above |
| 200 week MA | $86.6 | 17% above |
MDT is in an uptrend: it's above all five of its weekly moving averages, and 17% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $113.4 | $114.0 | +0.6% |
| 2021 | $114.0 | $102.9 | -9.8% |
| 2022 | $102.9 | $77.5 | -25% |
| 2023 | $77.5 | $82.4 | +6.3% |
| 2024 | $82.4 | $80.7 | -2% |
| 2025 | $80.7 | $96.5 | +20% |
| 2026 YTD | $96.5 | $101.0 | +4.6% |
MDT has finished lower in three of the last six years. It's up 4.6% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MDT on returns for 2026, with the stronger performance.